From: A neurodegenerative disease landscape of rare mutations in Colombia due to founder effects
Cohort | n | AAO | Female | APOE genotype no. (%) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ϵ2/ϵ2 | ϵ2/ϵ3 | ϵ2/ϵ4 | ϵ3/ϵ3 | ϵ3/ϵ4 | ϵ4/ϵ4 | ||||||||||||
Mean | Range | n | % | n | % | n | % | n | % | n | % | n | % | n | % | ||
AD | 376 | 59 | 30-90 | 249 | 66.2 | - | - | 15 | 4 | 4 | 1.1 | 168 | 45 | 139 | 37.1 | 49 | 13.1 |
FTLD-MND | 197 | 58.8 | 21-82 | 92 | 46.7 | 1 | 0.5 | 18 | 9.1 | - | - | 122 | 62 | 49 | 24.9 | 7 | 3.6 |
EOD | 73 | 54.5 | 25-75 | 49 | 67.1 | - | - | 2 | 2.7 | - | - | 39 | 53 | 20 | 27.4 | 12 | 16.4 |
Healthy | 254 | 60 | 18-100a | 159 | 62.6 | 2 | 0.8 | 25 | 9.8 | 1 | 0.4 | 159 | 45 | 61 | 23.9 | 4 | 1.6 |
 | 549 | 60.7 | 3 | 0.3 | 60 | 6.7 | 5 | 0.6 | 488 | 54.2 | 269 | 29.9 | 72 | 8 |